{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:29:03Z","timestamp":1790674143357,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40265-015-0477-8","type":"journal-article","created":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T07:37:13Z","timestamp":1444376233000},"page":"1823-1830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Cobimetinib: First Global Approval"],"prefix":"10.1007","volume":"75","author":[{"given":"Karly P.","family":"Garnock-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,9]]},"reference":[{"key":"477_CR1","doi-asserted-by":"crossref","unstructured":"Sullivan R, LoRusso P, Boerner S, et al. Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015:177\u201386. doi: 10.14694\/EdBook_AM.2015.35.177 .","DOI":"10.14694\/EdBook_AM.2015.35.177"},{"issue":"1","key":"477_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):27.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"477_CR3","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/S1470-2045(14)71023-X","volume":"15","author":"A Rahman","year":"2014","unstructured":"Rahman A. Vemurafenib and cobimetinib in BRAF-mutated melanoma. Lancet Oncol. 2014;15(12):e535.","journal-title":"Lancet Oncol"},{"key":"477_CR4","unstructured":"Exelixis. Exelixis (EXEL) announces first regulatory approval of cobimetinib in Switzerland [media release]. 27 Aug 2015. http:\/\/www.biospace.com\/ ."},{"key":"477_CR5","unstructured":"Roche Pharma. Cotellic\u00ae (cobimetinib tablets): Swiss prescribing information. 2015. https:\/\/compendium.ch . Accessed 4 Sep 2015."},{"key":"477_CR6","unstructured":"European Medicines Agency. CHMP summary of opinion (initial authorisation) for Cotellic (cobimetinib). 2015. http:\/\/www.ema.europa.eu . Accessed 28 Sep 2015."},{"key":"477_CR7","doi-asserted-by":"crossref","unstructured":"Exelixis. Exelixis signs co-development agreement with Genentech for small molecule oncology compound [media release]. 3 Jan 2007. http:\/\/www.exelixis.com .","DOI":"10.3833\/pdr.v2007i88.282"},{"key":"477_CR8","unstructured":"Exelixis. Option to develop Exelixis compound exercised by Genentech [media release]. 17 Mar 2008. http:\/\/www.exelixis.com ."},{"key":"477_CR9","unstructured":"Exelixis. Exelixis announces positive top-line results for phase 3 pivotal trial of cobimetinib in combination with vemurafenib in patients with BRAF V600 mutation-positive advanced melanoma [media release]. 14 Jul 2014. http:\/\/www.exelixis.com ."},{"key":"477_CR10","doi-asserted-by":"crossref","unstructured":"Exelixis. Exelixis announces first quarter 2007 financial results and business update [media release]. 3 May 2007. http:\/\/www.exelixis.com .","DOI":"10.3833\/pdr.v2007i88.282"},{"issue":"5","key":"477_CR11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1021\/ml300049d","volume":"3","author":"KD Rice","year":"2012","unstructured":"Rice KD, Aay N, Anand NK, et al. Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973). ACS Med Chem Lett. 2012;3(5):416\u201321.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"477_CR12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2191-219X-2-22","volume":"2","author":"AR Baudy","year":"2012","unstructured":"Baudy AR, Dogan T, Flores-Mercado JE, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res. 2012;2(1):22.","journal-title":"EJNMMI Res"},{"issue":"Supplement 4","key":"477_CR13","doi-asserted-by":"crossref","first-page":"iv378","DOI":"10.1093\/annonc\/mdu344.9","volume":"25","author":"Y Yan","year":"2014","unstructured":"Yan Y, McArthur G, Gajewski T, et al. Vemurafenib and cobimetinib potently inhibit PS6 signaling in BRAFV600 mutation-positive locally advanced or metastatic melanoma from BRIM7 study [abstract no. 1093PD]. Ann Oncol. 2014;25(Supplement 4):iv378.","journal-title":"Ann Oncol."},{"issue":"Supplement 6","key":"477_CR14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0959-8049(14)70513-1","volume":"50","author":"M Merchant","year":"2014","unstructured":"Merchant M, Chan J, Orr C, et al. Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor models [abstract no. 387]. Eur J Cancer. 2014;50(Supplement 6):124.","journal-title":"Eur J Cancer"},{"issue":"Supplement 2","key":"477_CR15","first-page":"S736","volume":"49","author":"O Aslan","year":"2013","unstructured":"Aslan O, Farrelly AM, Stordal B, et al. Anti-tumour efficacy of the PI3\u00a0K inhibitor GDC0941, the dual PI3K\/mTOR inhibitor GDC0980 and the MEK inhibitor GDC0973 as single agents and in combination in endometrial carcinomas [abstract no. 3079]. Eur J Cancer. 2013;49(Supplement 2):S736.","journal-title":"Eur J Cancer"},{"key":"477_CR16","unstructured":"Belvin M, Berry L, Chan J, et al. Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumour growth inhibition in vivo [abstract no. 132]. JCC Suppl. 2010;8(7):48."},{"key":"477_CR17","doi-asserted-by":"crossref","unstructured":"Musib L, Eppler S, Choo E, et al. Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study [abstract no. 1304]. Cancer Res. 2011;71(8 Supplement).","DOI":"10.1158\/1538-7445.AM2011-1304"},{"issue":"11","key":"477_CR18","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1021\/mp400383x","volume":"10","author":"L Musib","year":"2013","unstructured":"Musib L, Choo E, Deng Y, et al. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm. 2013;10(11):4046\u201354.","journal-title":"Mol Pharm"},{"issue":"11","key":"477_CR19","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1158\/1078-0432.CCR-12-0445","volume":"18","author":"H Wong","year":"2012","unstructured":"Wong H, Vernillet L, Peterson A, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012;18(11):3090\u20139.","journal-title":"Clin Cancer Res"},{"key":"477_CR20","doi-asserted-by":"crossref","unstructured":"Choo E, Takahashi R, Rooney I, et al. Assessing human absorption, metabolism, routes of excretion and the contribution of intestinal metabolism to the oral clearance of cobimetinib, a MEK inhibitor [abstract no. B160]. Mol Cancer Ther. 2013;12(11 Suppl. 1).","DOI":"10.1158\/1535-7163.TARG-13-B160"},{"key":"477_CR21","doi-asserted-by":"crossref","unstructured":"Han K, Jin J, Marchand M, et al. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors [abstract no. 2573]. J Clin Oncol. 2015;33(Supplement).","DOI":"10.1007\/s00280-015-2862-0"},{"issue":"11","key":"477_CR22","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1021\/mp500435s","volume":"11","author":"EF Choo","year":"2014","unstructured":"Choo EF, Ly J, Chan J, et al. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib. Mol Pharm. 2014;11(11):4199\u2013207.","journal-title":"Mol Pharm"},{"issue":"20","key":"477_CR23","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376.","journal-title":"N Engl J Med"},{"key":"477_CR24","doi-asserted-by":"crossref","unstructured":"Paolo Antonio A, Luis De La C-M, Daniil S, et al. Update of progression-free survival (PFS) and correlative biomarker analysis from CoBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma [abstract no. 9006]. J Clin Oncol. 2015;33(15 Supplement).","DOI":"10.1200\/jco.2015.33.15_suppl.9006"},{"issue":"9","key":"477_CR25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","volume":"15","author":"A Ribas","year":"2014","unstructured":"Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15(9):954\u201365.","journal-title":"Lancet Oncol."},{"key":"477_CR26","doi-asserted-by":"crossref","unstructured":"Pavlick AC, Ribas A, Gonzalez R, et al. Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma [abstract no. 9020]. J Clin Oncol. 2015;33(15).","DOI":"10.1200\/jco.2015.33.15_suppl.9020"},{"key":"477_CR27","doi-asserted-by":"crossref","unstructured":"Bendell JC, LoRusso P, Cho DC, et al. Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors [abstract no. CT328]. Cancer Res. 2014;74(19 Suppl. 1).","DOI":"10.1158\/1538-7445.AM2014-CT328"},{"key":"477_CR28","doi-asserted-by":"crossref","unstructured":"Russo PL, Shapiro G, Pandya SS, et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3\u00a0K inhibitor GDC-0941, in patients with advanced solid tumors [abstract no. 2566]. J Clin Oncol. 2012;30(15 Suppl. 1).","DOI":"10.1200\/jco.2012.30.15_suppl.2566"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0477-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0477-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0477-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T12:38:42Z","timestamp":1599655122000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0477-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0477-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}